# Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study

Paul Simon, Pierrick Le Borgne, François Lefebvre, Lauriane Cipolat, Aline Remillon, Camille Dib, Mathieu Hoffmann, Idalie Gardeur, Jonathan Sabah, Sabrina Kepka, et al.

► To cite this version:

Paul Simon, Pierrick Le Borgne, François Lefebvre, Lauriane Cipolat, Aline Remillon, et al., Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study. Journal of Clinical Medicine, 2022, 11 (16), pp.4903. 10.3390/jcm11164903. [https://doi.org/10.3390/jcm11164903](https://doi.org/10.3390/jcm11164903)

HAL Id: hal-05484304

https://univoak.hal.science/hal-05484304v1

Submitted on 29 Jan 2026

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
Article

# Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study

Paul Simon<sup>1,2</sup>, Pierrick Le Borgne<sup>1,3 ID</sup>, François Lefebvre<sup>4</sup>, Lauriane Cipolat<sup>5</sup>, Aline Remillon<sup>5</sup>, Camille Dib<sup>5</sup>, Mathieu Hoffmann<sup>5</sup>, Idalie Gardeur<sup>5</sup>, Jonathan Sabah<sup>6</sup>, Sabrina Kepka<sup>1</sup>, Pascal Bilbault<sup>1,2,3 ID</sup>, Charles-Eric Lavoignet<sup>7</sup> and Laure Abensur Vuillaume<sup>5,* ID</sup> on behalf of the CREMS Network (Clinical Research in Emergency Medicine and Sepsis)

1. Emergency Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France

2. Medicine Faculty, Strasbourg University, 67000 Strasbourg, France

3. INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), Fédération de Médecine Translationnelle (FMTS), 67000 Strasbourg, France

4. Department of Public Health, University Hospital of Strasbourg, 67000 Strasbourg, France

5. Emergency Department, Regional Hospital of Metz-Thionville, 57000 Metz, France

6. Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France

7. Emergency Department, Hôpital Nord Franche Comté, 90400 Trévenans, France

* Correspondence: l.abensurvuillaume@chr-metz-thionville.fr

<figure><img src="image_2.png" /></figure>

check for
updates

**Citation:** Simon, P.; Le Borgne, P.; Lefebvre, F.; Cipolat, L.; Remillon, A.; Dib, C.; Hoffmann, M.; Gardeur, I.; Sabah, J.; Kepka, S.; et al. Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study. *J. Clin. Med.* **2022**, *11*, 4903. https://doi.org/10.3390/jcm11164903

Academic Editor: Alessandra D'Abramo

Received: 30 July 2022

Accepted: 19 August 2022

Published: 21 August 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_3.png" /></figure>

**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** (1) Introduction: In the present study, we investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) as a marker of severity and mortality in COVID-19 infection. (2) Methods: Between 1 March and 30 April 2020, we conducted a multicenter, retrospective cohort study of patients with moderate to severe coronavirus 19 (COVID-19), all of whom were hospitalized after being admitted to the emergency department (ED). (3) Results: A total of 1035 patients were included in our study. Neither lymphocytes, platelets or PLR were associated with disease severity. Lymphocyte count was significantly lower and PLR values were significantly higher in the group of patients who died, and both were associated with mortality in the univariate analysis (OR: 0.524, 95% CI: (0.336–0.815), *p* = 0.004) and (OR: 1.001, 95% CI: (1.000–1.001), *p* = 0.042), respectively. However, the only biological parameter significantly associated with mortality in the multivariate analysis was platelet count (OR: 0.996, 95% CI: (0.996–1.000), *p* = 0.027). The best PLR value for predicting mortality in COVID-19 was 356.6 (OR: 3.793, 95% CI: (1.946–7.394), *p* < 0.001). (4) Conclusion: A high PLR value is however associated with excess mortality.

**Keywords:** PLR; platelet-to-lymphocyte ratio; severity; mortality; COVID-19

## 1. Introduction

It has been over two years that the world has been facing an unprecedented health crisis that is straining health systems. Since the first cases were identified in December 2019 in Wuhan, China [1], this pandemic caused by a new virus of the coronavirus family called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) [2] has caused more than 6 million deaths for more than 500 million cases worldwide [3]. In France, after five waves, taking account that the first one particularly affected the Grand-East region from which our database originates, there have been over 146,000 deaths for more than 28 million cases [4]. COVID-19 (Coronavirus Disease 2019), the disease caused by this virus [2], is known mainly in its severe forms to be responsible for multi-organ failure and Acute Respiratory Distress Syndrome (ARDS). Pulmonary lesions are partly mediated by a dysregulation of the immune system leading to a “cytokine storm”, as evidenced by excessive secretion of pro-inflammatory cytokines, notably, GM-CSF, IL-6 and TNF-α [5].
It has been observed that routine laboratory tests were affected by COVID-19 with variable frequencies, such as depending on the series, 5–41.7% thrombocytopenia or up to 83% lymphopenia observed in infected patients [6,7]. Numerous studies have therefore focused on the correlation between these biological abnormalities, especially biomarkers reflecting inflammation, and the development of severe COVID-19. In addition to being associated with the development of ARDS, some biological abnormalities are also correlated with increased mortality from SARS-CoV-2: in a meta-analysis including 21 studies and finding similar results to other papers [7–10], Brandon et al. showed that significantly lower lymphocyte and platelet counts are associated with patient death compared to surviving patients, as well as increased ALT, creatinine, LDH, PT and ferritin [11]. In addition, other studies have looked more specifically at lymphopenia. Qin et al. showed in their study a significant decrease in the total number of B, T and NK cells, this decrease being even more pronounced in severe cases. T cells were shown to be more affected and they noticed a significant decrease in the regulatory T-cells subpopulation (CD3+, CD4+, CD25+, CD127low+) (9). Wang et al. obtained similar results, also finding a significant decrease in the subpopulations of CD4+ and CD8+ T cells. Here, again, the decline was even greater in severe forms, with the exception of LNK [12].

However, these biological parameters remain relatively nonspecific and the use of a combined marker, such as the platelet-to-lymphocyte ratio (PLR), could provide an additional argument to better discriminate patients at risk of developing a severe SARS-CoV-2 infection. Indeed, the PLR seems to reflect changes in platelet and lymphocyte levels related to inflammation and a pro-thrombotic state [13], which seems to be the lesioning mechanism of SARS-CoV-2. This new biomarker, which reflects inflammatory processes, is also being studied in several other types of pathologies where it provides prognostic elements or activity monitoring. In oncology, in a meta-analysis, Templeton et al. showed that a higher PLR, particularly a PLR > 185, was associated with poorer overall survival, with a pooled HR of 1.70 (95% CI, 1.47–1.95; *p* < 0.001) [14]. In a review, Gasparyan et al. summarized the research on PLR in rheumatic diseases and concluded that it can help in the diagnosis and evaluation of the activity and severity of those diseases [15]. In cardiovascular disease, Akboga et al. showed that PLR was an independent predictor of severe coronary artery disease (OR 1.043 [1.036–1.049], *p* < 0.001) and determined that an PLR > 109.5 had a sensitivity of 70%, specificity of 58% for predicting the presence of severe coronary atherosclerosis (AUC: 0.708, 95% CI: (0.68–0.73), *p* < 0.001) [16]. Meng et al. observed that in an acute non-ST-segment elevation myocardial infarction, a PLR ≥ 195.8 was significantly associated with increased 28-day mortality (HR 1.54; 95% CI: (1.09–2.18); *p* = 0.013) [17].

This study aims to assess the prognostic value of PLR in the severity and mortality of patients infected with SARS-CoV-2 on admission to the emergency department (ED).

## 2. Materials and Methods

### 2.1. *Study Population and Settings*

We conducted a multicentric retrospective study in six EDs in the North-East region of France. We led our study in two university hospitals (CHRU of Strasbourg in Strasbourg and CHU of Reims in Reims, France) and four general hospitals (Colmar Hospital in Colmar, Nord Franche-Comté Hospital in Belfort, Metz-Thionville Hospital in Metz and Thionville and Haguenau Hospital in Haguenau, France). These hospital centers, along with the entire Greater-East region of France, were one of the outbreak's epicenters in Europe during the first wave.

We included all adult patients hospitalized for COVID-19 after being admitted to the ED between 1 March and 30 April 2020. All patients included in our study had a laboratory-confirmed diagnosis of COVID-19 by RT-PCR on nasopharyngeal swab (on admission). Exclusion criteria were patients who had a non-confirmed diagnosis, or those who have received outpatient care, and those who had received palliative therapy or limitation of therapeutic effort upon admission to the ED. The exclusion criteria were also patients
with a medical background or treatment modifying their blood count and, therefore, their circulating lymphocyte or platelet counts (e.g., chemotherapy, immunosuppressive therapy, long- and short-term corticosteroid therapies, pre-admission antibiotic therapy, active cancer or hematological malignancies).

## 2.2. Data Collection

We retrospectively collected epidemiological, clinical and biochemical data from the patients' electronic medical records, and standardized results in a report file. We recorded symptom onset data along with the patient's current treatment and medical background (including cardiovascular disease, diabetes, pre-existing renal failure, cancer and hematological diseases). The primary endpoint was the prognostic value of PLR on COVID-19 mortality upon ED admission. The secondary endpoint was its prognostic value on COVID-19 severity upon ED admission. The severity of COVID-19 disease was defined by patient admission into the ICU (intensive care unit), which, during the first wave of the pandemic, was mainly associated with invasive mechanical ventilation indication. Moderate disease was defined by patient admission to conventional hospitalization units and, in fine, the requirement for simple or high-flow oxygen therapy. Ambulatory patients were excluded. Obesity was defined by a body mass index superior to 30 kg/m². Standard biological parameters were collected, such as levels of creatinine, CRP, platelet count, total leukocytes and lymphocytes. Lastly, we calculated PLR values at ED admission, the ratio of platelets to circulating lymphocytes. All collected data are summarized in the Tables and Results sections.

## 2.3. Ethics

This study was approved by the local ethics committee of the University of Strasbourg in France (reference CE: 2020-39), which, in accordance with the French legislation, waived the need for informed consent of patients whose data were entirely retrospectively studied.

## 2.4. Statistical Analysis

The statistical analyses included a descriptive and an analytical section. We performed the descriptive analysis of the qualitative variables by providing the frequency of each value. We compared them in a univariate analysis by using chi-squared or Fisher's tests in case the expected values in any of the cells of a contingency table was below 5. We performed the descriptive analysis of the continuous variables by providing median, and first and third quartiles of each value. We compared them in an univariate analysis by using a non-parametric Mann-Whitney test or, in case the variables followed a normal distribution by using a Welsh's test. Using statistically significant results obtained from univariate analyses and clinically relevant variables, a multivariate logistic model was performed to assess disease severity, then the in-hospital mortality. A backward stepwise method was performed. Receiver operating characteristic (ROC) curves were constructed and the best cut-off value of PLR discriminating severe from moderate patients, and patients who died during their stay from those who survived were determined by using the Yunden's index. *p*-values < 0.05 were considered significant and the confidence interval (CI) was 95%. Analyses were performed with the R software in version 4.0.2 (R Core Team 2020. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria), as well as with all the software packages required to conduct the analysis.

# 3. Results

## 3.1. Characteristics of the Study Population

During the study period, a total of 49,326 patients were admitted to the EDs of all six hospitals. Of these patients, 4470 had a laboratory-confirmed SARS-CoV-2 infection, 1685 received ambulatory care, 1750 met the exclusion criteria and, in fine, 1035 patients were included in our study (flowchart: Figure 1).
<figure><img src="image_4.png" /><figcaption>**Figure 1.** Flowchart of the study. Legend: ED: emergency department, ICU: intensive care unit, COVID-19: coronavirus disease.</figcaption></figure>

Our cohort had a median age of 69 (58.0–79.0) years and was predominately male (58.8%). Regarding the comorbidities, 1/3 of our study population was obese (36.9%) and had coronary heart disease (34.5%), over 1/2 of the patients (56.7%) had hypertension, over 1/4 of them (26.6%) had a history of diabetes and 23.2% of them presented chronic kidney disease. Only 5.4% had chronic obstructive lung disease. At admission, even if the median lymphocyte count was significantly lower in the group presenting severe COVID-19 compared to that with moderate COVID-19 (0.780, 95% CI: (0.590–1.122)) vs. 0.900, 95% CI: (0.640–1.220), *p* = 0.003)), we did not find a significant difference between these two groups for platelet count and PLR. The main clinical and biochemical patient characteristics are summarized in Table 1.

<table><caption>**Table 1.** General characteristics, comorbidities and laboratory findings of study population with moderate and severe COVID-19.</caption><thead><tr><th></th><th></th><th>All Patients<br>(n = 1035)</th><th>Moderate COVID-19<br>(n = 789)</th><th>Severe COVID-19<br>(n = 246)</th><th>p</th></tr></thead><tbody><tr><td>Characteristics</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age (years)</td><td></td><td>69.0 (58.0–79.0)</td><td>70.0 (58.0–81.0)</td><td>66.0 (57.3–72.0)</td><td>&lt;0.001 *</td></tr><tr><td>Gender male</td><td></td><td>609 (58.8)</td><td>433 (54.9)</td><td>176 (71.5)</td><td>&lt;0.001 *</td></tr><tr><td>Current smoker</td><td></td><td>46 (4.4)</td><td>34 (4.3)</td><td>12 (4.9)</td><td>0.706</td></tr><tr><td>Comorbidities</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Hypertension</td><td></td><td>587 (56.7)</td><td>453 (57.4)</td><td>134 (54.5)</td><td>0.416</td></tr><tr><td>Diabetes</td><td></td><td>275 (26.6)</td><td>202 (25.6)</td><td>73 (29.7)</td><td>0.207</td></tr><tr><td rowspan="2">Obesity</td><td>BMI (kg/m<sup>2</sup>) (30, 40)</td><td>253 (33.2)</td><td>172 (31.2)</td><td>81 (38.6)</td><td>0.056</td></tr><tr><td>BMI (kg/m<sup>2</sup>) ≥ 40</td><td>28 (3.7)</td><td>21 (3.8)</td><td>7 (3.3)</td><td>0.966</td></tr></tbody></table>
<table><caption>**Table 1.** *Cont.*</caption><thead><tr><th></th><th>All Patients<br>(n = 1035)</th><th>Moderate COVID-19<br>(n = 789)</th><th>Severe COVID-19<br>(n = 246)</th><th>p</th></tr></thead><tbody><tr><td>COPD</td><td>56 (5.4)</td><td>44 (5.6)</td><td>12 (4.9)</td><td>0.672</td></tr><tr><td>Chronic kidney disease</td><td>237 (23.2)</td><td>199 (25.5)</td><td>38 (15.8)</td><td>0.002 *</td></tr><tr><td>Coronary heart disease</td><td>357 (34.5)</td><td>291 (36.9)</td><td>66 (26.8)</td><td>0.004 *</td></tr><tr><td>Laboratory findings</td><td></td><td></td><td></td><td></td></tr><tr><td>Lymphocyte count, ×10<sup>9</sup> per L</td><td>0.870 (0.630–1.200)</td><td>0.900 (0.640–1.220)</td><td>0.780 (0.590–1.122)</td><td>0.003 *</td></tr><tr><td>Platelet count, ×10<sup>9</sup> per L</td><td>194.5 (152.0–248.0)</td><td>196.0 (154.0–247.0)</td><td>192.0 (144.0–253.0)</td><td>0.518</td></tr><tr><td>PLR</td><td>223.3 (156.5–329.0)</td><td>219.9 (154.7–320.5)</td><td>238.5 (162.4–357.7)</td><td>0.061</td></tr><tr><td>Outcomes</td><td></td><td></td><td></td><td></td></tr><tr><td>Mortality</td><td>139 (13.6)</td><td>82 (10.4)</td><td>57 (24.1)</td><td>&lt;0.001 *</td></tr><tr><td>Length of hospital stay (days)</td><td>10.0 (7.0–17.3)</td><td>8.0 (6.0–12.0)</td><td>24.0 (17.0–38.0)</td><td>&lt;0.001 *</td></tr></tbody></table>

Data are all expressed in median (Q1–Q3) or n (%) where n is the total number of patients with available data. * *p* < 0.05. Legend: BMI: body mass index, COPD: chronic obstructive pulmonary disease, PLR: platelet-to-lymphocyte ratio.

We performed the analysis to observe if there was any interest in carrying on our study and if there was a difference in PLR between living and dead patients. The median PLR was significantly higher in the group of patients who died compared to those who survived (242.3, 95% CI: (164.6–385.7) vs. 221.4, 95% CI: (154.7–319.4), *p* = 0.043)); Table 2.

<table><caption>**Table 2.** General characteristics, comorbidities and laboratory findings of the study population, surviving and dying from COVID-19.</caption><thead><tr><th></th><th></th><th>All Patients<br>(n = 1035)</th><th>Survivor<br>(n = 884)</th><th>Non Survivor<br>(n = 139)</th><th>p</th></tr></thead><tbody><tr><td>Characteristics</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age (years)</td><td></td><td>69.0 (58.0–79.0)</td><td>67.0 (56.0–77.0)</td><td>78.0 (70.0–86.0)</td><td>&lt;0.001 *</td></tr><tr><td>Gender male</td><td></td><td>609 (58.8)</td><td>517 (58.5)</td><td>85 (61.2)</td><td>0.553</td></tr><tr><td>Current smoker</td><td></td><td>46 (4.4)</td><td>42 (4.8)</td><td>4 (2.9)</td><td>0.322</td></tr><tr><td>Comorbidities</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Hypertension</td><td></td><td>587 (56.7)</td><td>477 (54.0)</td><td>103 (74.1)</td><td>&lt;0.001 *</td></tr><tr><td>Diabetes</td><td></td><td>275 (26.6)</td><td>227 (25.7)</td><td>42 (30.2)</td><td>0.259</td></tr><tr><td rowspan="2">Obesity</td><td>BMI (30, 40)</td><td>253 (33.2)</td><td>222 (33.1)</td><td>30 (34.9)</td><td>0.889</td></tr><tr><td>BMI ≥ 40</td><td>28 (3.7)</td><td>27 (4.0)</td><td>1 (1.2)</td><td>0.191</td></tr><tr><td>COPD</td><td></td><td>56 (5.4)</td><td>38 (4.3)</td><td>18 (13.0)</td><td>&lt;0.001 *</td></tr><tr><td>Chronic kidney disease</td><td></td><td>237 (23.2)</td><td>189 (21.6)</td><td>47 (35.3)</td><td>&lt;0.001 *</td></tr><tr><td>Coronary heart disease</td><td></td><td>357 (34.5)</td><td>283 (32.1)</td><td>72 (51.8)</td><td>&lt;0.001 *</td></tr><tr><td>Laboratory findings</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lymphocyte count, ×10<sup>9</sup> per L</td><td></td><td>0.870 (0.630–1.200)</td><td>0.890 (0.650–1.220)</td><td>0.720 (0.500–1.000)</td><td>&lt;0.001 *</td></tr><tr><td>Platelet count, ×10<sup>9</sup> per L</td><td></td><td>194.5 (152.0–248.0)</td><td>196.0 (153.3–248.0)</td><td>181.0 (138.3–246.0)</td><td>0.031 *</td></tr><tr><td>PLR</td><td></td><td>223.3 (156.5–329.0)</td><td>221.4 (154.7–319.4)</td><td>242.3 (164.6–385.7)</td><td>0.043 *</td></tr></tbody></table>
<table><caption>**Table 2.** *Cont.*</caption><thead><tr><th></th><th>All Patients<br>(n = 1035)</th><th>Survivor<br>(n = 884)</th><th>Non Survivor<br>(n = 139)</th><th>p</th></tr></thead><tbody><tr><td>C-reactive protein, mg/L</td><td>81.0 (39.0–142.0)</td><td>78.5 (37.0–139.0)</td><td>100.0 (56.0–158.0)</td><td>0.008 *</td></tr><tr><td>Creatinine, µmol/L</td><td>78.0 (64.0–98.0)</td><td>76.0 (62.0–94.0)</td><td>96.0 (77.5–144.5)</td><td>&lt;0.001 *</td></tr><tr><td>Lactate, mmol/l</td><td>1.2 (0.9–1.6)</td><td>1.2 (0.9–1.5)</td><td>1.4 (1.1–1.9)</td><td>&lt;0.001 *</td></tr></tbody></table>

Data are all expressed in median (Q1–Q3) or n (%) where n is the total number of patients with available data. *p* < 0.05. Legend: BMI: body mass index, COPD: chronic obstructive pulmonary disease, PLR: platelet-to-lymphocyte ratio.

## 3.2. *Biochemical Factors Associated and Factors Predicting COVID-19 Severity*

Of the entire study population, 789 patients (76.2%) had moderate disease, whereas 246 (23.8%) had severe disease requiring ICU management. When comparing these two subgroups, age (70 vs. 66 years, *p* < 0.001) and gender (*p* < 0.001) differed significantly. Patients admitted to the ICU had fewer cardiovascular (*p* = 0.004) and renal (*p* = 0.002) comorbidities. In the multivariate analysis, adjusted for age, gender, complications, and laboratory findings following a backward stepwise selection, none of the parameters studied were associated with the severity of infection. The results are summarized in Table 3.

<table><caption>**Table 3.** Univariate and multivariate analyses for risk factor for COVID-19 severity.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">All Patients</th><th rowspan="2">Moderate COVID-19</th><th rowspan="2">Severe COVID-19</th><th colspan="2">Univariate Analysis</th><th colspan="2">Multivariate Analysis</th></tr><tr><th>OR (95% CI)</th><th>p</th><th>OR (95% CI)</th><th>p</th></tr></thead><tbody><tr><td>Lymphocyte count, 10<sup>9</sup> per L</td><td>0.870 (0.630–1.200)</td><td>0.900 (0.640–1.220)</td><td>0.780 (0.590–1.122)</td><td>0.827 (0.616–1.110)</td><td>0.206</td><td>0.937 (0.647–1.357)</td><td>0.729</td></tr><tr><td>Platelet count, 10<sup>9</sup> per L</td><td>194.5 (152.0–248.0)</td><td>196.0 (154.0–247.0)</td><td>192.0 (144.0–253.0)</td><td>1.000 (0.998–1.002)</td><td>0.979</td><td>1.000 (0.998–1.003)</td><td>0.765</td></tr><tr><td>PLR</td><td>223.3 (156.5–329.0)</td><td>219.9 (154.7–320.5)</td><td>238.5 (162.4–357.7)</td><td>1.000 (1.000–1.001)</td><td>0.107</td><td>1.001 (1.000–1.001)</td><td>0.107</td></tr></tbody></table>

Data are all expressed in median (Q1–Q3) or n (%) where n is the total number of patients with available data. Legend: OR: odds ratio, CI: confidence interval, PLR: platelet-to-lymphocyte ratio.

We made a receiver operating characteristics (ROC) curve to predict the risk of disease severity. Regarding the PLR during admission, the area under the curve (AUC) was 0.54 (95% CI: (0.497–0.582)). The best cut-off for predicting the risk of infection severity was 369.7; it yielded a sensitivity of 23.8% (95% CI: (18.6–29.7)) and specificity of 83.8% (95% CI: (81.0–86.3)). In the multivariate analysis, if PLR was greater than 369.7, the OR was valued at 1.884 (95% CI: (1.130–140), *p* = 0.015) (Figure 2).

## 3.3. *Biochemical Factors Associated and Factors Predicting COVID-19 Mortality*

Mortality analysis included 1023 patients, as 12 patients (1.2%) were lost to follow-up. A total of 139 patients died during their hospital stay, representing 13.6% of our cohort, while 884 (86.4%) survived. Non-surviving patients were significantly older (78 versus 67 years, *p* < 0.001). They were more likely to have a medical history of hypertension (*p* < 0.001), chronic obstructive lung disease (*p* < 0.001), chronic kidney disease (*p* < 0.001) and coronary heart disease (*p* < 0.001). Biochemically, higher levels of creatinine (96.0, 95% CI: (77.5–144.5) vs. 76.0, 95% CI: (62.0–94.0), *p* < 0.001), CRP (100.0, 95% CI: (56.0–158.0) vs. 78.5, 95% CI: (37.0–139.0), *p* = 0.008) and lactate (1.4, 95% CI: (1.1–1.9) vs. 1.2, 95% CI: (0.9–1.5), *p* < 0.001) were observed in the non-surviving subgroup. Regarding the cell blood count, lymphopenia was more profound (0.720, 95% CI: (0.500–1.000) vs. 0.890, 95% CI: (0.650–1.220), *p* < 0.001), and platelet count was significantly lower (181.0, 95% CI: (138.3–246.0) vs. 196.0, 95% CI: (153.3–248.0), *p* = 0.031) in the non-surviving subgroup. Upon admission to the ED, the lymphocyte count was significantly lower and PLR values were significantly higher, and both were associated with mortality in univariate analysis
(respectively, *p* = 0.004 and *p* = 0.042). However, the only biochemical parameter significantly associated with mortality in multivariate analysis was the platelet count (OR: 0.996, 95% CI: (0.996–1.000), *p* = 0.027). These results are summarized in Table 4.

<figure><img src="image_5.png" /></figure>

<table><thead><tr><th rowspan="2">To Predict COVID-19 Severity</th><th rowspan="2">AUC</th><th rowspan="2">Cut-Off</th><th rowspan="2">Sensitivity</th><th rowspan="2">Specificity</th><th colspan="2">Multivariate Analysis with Cut-Off</th></tr><tr><th>OR (95% CI)</th><th><i>p</i></th></tr></thead><tbody><tr><td>PLR</td><td>54.0 (49.7–58.2)</td><td>369.7</td><td>0.24 (0.19–0.30)</td><td>0.84 (0.81–0.86)</td><td>1.884 (1.130–3.140)</td><td>0.015 *</td></tr></tbody></table>

Legend—AUC: area under curve; PLR: platelet-to-lymphocyte ratio; OR: odds ratio; CI: confidence interval, * *p* < 0.005.

<caption>**Figure 2.** Receiver operating characteristics (ROC) curve for PLR as a predictive factor of severe COVID-19.</caption>

<table><caption>**Table 4.** Univariate and multivariate analyses for risk factors for COVID-19 mortality.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">All Patients</th><th rowspan="2">Survivor</th><th rowspan="2">Non Survivor</th><th colspan="2">Univariate Analysis</th><th colspan="2">Multivariate Analysis</th></tr><tr><th>OR (95% CI)</th><th><i>p</i></th><th>OR (95% CI)</th><th><i>p</i></th></tr></thead><tbody><tr><td>Lymphocyte count, 10<sup>9</sup> per L</td><td>0.870 (0.630–1.200)</td><td>0.890 (0.650–1.220)</td><td>0.720 (0.500–1.000)</td><td>0.524 (0.336–0.815)</td><td>0.004 *</td><td>0.756 (0.393–1.456)</td><td>0.403</td></tr><tr><td>Platelet count, ×10<sup>9</sup> per L</td><td>194.5 (152.0–248.0)</td><td>196.0 (153.3–248.0)</td><td>181.0 (138.3–246.0)</td><td>0.998 (0.995–1.000)</td><td>0.078</td><td>0.996 (0.992–1.000)</td><td>0.027 *</td></tr><tr><td>PLR</td><td>223.3 (156.5–329.0)</td><td>221.4 (154.7–319.4)</td><td>242.3 (164.6–385.7)</td><td>1.001 (1.000–1.001)</td><td>0.042 *</td><td>1.000 (0.999–1.002)</td><td>0.444</td></tr></tbody></table>

Data are all expressed in median (Q1–Q3) or *n* (%) where *n* is the total number of patients with available data.
* *p* < 0.05. Legend: OR: odds ratio, CI: confidence interval, PLR: platelet-to-lymphocyte ratio.

We created receiver operating characteristics (ROC) curves to predict the risk of disease mortality. Regarding the PLR at admission, the area under the curve (AUC) was 0.55 (95% CI: (0.498–0.611)). The best cut-off for predicting the risk of infection severity was 356.6: it yielded a sensibility of 34.3% (95% CI: (26.3–43.0)) and a specificity of 82.4% (95% CI: (79.7–84.9)). In the multivariate analysis, if the PLR was greater than 356.6, the OR was valued at 3.793 (95% CI: (1.946–7.394), *p* < 0.001) (Figure 3).
<figure><img src="image_6.png" /></figure>

<table><thead><tr><th rowspan="2">To Predict COVID-19 Severity</th><th rowspan="2">AUC</th><th rowspan="2">Cut-Off</th><th rowspan="2">Sensitivity</th><th rowspan="2">Specificity</th><th colspan="2">Multivariate Analysis with Cut-Off</th></tr><tr><th>OR (95% CI)</th><th>p</th></tr></thead><tbody><tr><td>PLR</td><td>55.4 (49.8–61.1)</td><td>356.6</td><td>0.3433 (0.26–0.43)</td><td>0.8243 (0.80–0.85)</td><td>3.793 (1.946–7.394)</td><td>&lt;0.001 *</td></tr></tbody></table>

Legend—AUC: area under curve; PLR: platelet-to-lymphocyte ratio; OR: odds ratio; CI: confidence interval, * p < 0.005.

<caption>**Figure 3.** Receiver operating characteristics (ROC) curve for PLR as a predictive factor of COVID-19 mortality.</caption>

## 4. Discussion

The aim of our study was to investigate the prognostic value of the PLR in a cohort of SARS-CoV-2-infected patients from their admission to the ED. We selected our patients as carefully as possible to limit confounding factors that could have altered the CBC. Our study did not show significant results to recognize PLR as an efficient marker to discriminate among hospitalized patients, those likely to develop a severe form and requiring ICU management. Furthermore, in the univariate analysis, the PLR was significantly higher in patients who died compared to those who survived, although this association was not observed in the multivariate analysis.

The results of the studies investigating PLR in COVID-19 remain heterogeneous. Some studies seem to indicate that the PLR would be an efficient predictive marker of the severity and mortality of COVID-19, which slightly differs according to our results. In addition to the limited number of subjects, which may be responsible for the lack of power presented in these studies and explain the difference of results, it is important to notice that the inclusion criteria were also different in other studies. Indeed, some authors used a control group of COVID-19-negative patients as a comparison [18,19]. Others, including a majority of the studies from China, had inclusion criteria that referred to the criteria met from the General Office of the National Health Commission of China [20] and classified patients into two subgroups: “mild” and “common”, which, in our study, met the exclusion criteria [21–23]. Finally, the PLR was higher and appeared to be a valuable marker to discriminate non-infected patients from infected patients, such as patients with pauci-symptomatic forms of the disease from patients meeting the hospitalization criteria. However, the PLR did not make it possible to discriminate between moderate and severe forms requiring intensive care management. Wang R et al., in a study with a patient selection similar to ours, were one of the few researchers to obtain results for the PLR that were similar to our study. The
PLR was significatively higher in the non-surviving group compared to the surviving group (237.32, CI 95%: (160.15–400.96) vs. 173.29, CI 95%: (132.35–252.22), *p* < 0.001), and in the univariate analysis there was an association between a high PLR and mortality (OR: 1.004, CI 95%: (1.002–1.05), *p* < 0.001), which they did not observe in the multivariate analysis (OR: 1.003, CI 95%: (0.999–1.007), *p* = 0.154) [24].

Another particularity of our study was its exclusion criteria. Indeed, we decided to exclude patients with comorbidities or treatments that could alter the CBC and modify the PLR. However, there were some situations where the PLR was often increased, with a negative correlation with the underlying disease, and which had a poor prognosis in the case of SARS-CoV-2 infection. Solid cancers, for example, have been described as a risk factor for mortality in COVID-19 [10,25] cases and a high PLR was associated with advanced disease and mortality [14,26]. Similarly, we excluded patients who received corticosteroid therapy, which tends to increase the platelet count and to a lesser extent the lymphocyte count [27], and thus increase the PLR. However, corticosteroid therapy is now an integral part of the treatment used for COVID-19 [28].

From a pathophysiological point of view, several causes are put forward to explain lymphopenia and thrombocytopenia. Lymphopenia could be linked to a cell-exhaustion phenomenon, direct viral lymphocyte infection, bone marrow infection, apoptosis of lymphocytes led by inflammation and inhibition of lymphocytes by metabolic dysregulation [29,30]. Thrombocytopenia is essentially linked to platelet consumption, but also to lower levels of production due to bone marrow damage and to an immunological phenomenon leading to platelet destruction [31]. However, since those do not appear from the same mechanism, the onset speed of these two biological anomalies differs. Studies have analyzed the evolution of these biological abnormalities during infection. Indeed, there is high variability over time concerning the number of platelets and lymphocytes, particularly during the early onset of the disease [32–35]. This also raises the question of PLR’s variability and its interpretation. According to our results, we can also ask ourselves about the utility of this ratio and, more broadly, the contribution of biological ratios that have emerged in recent years, such as the neutrophil-to-lymphocyte ratio (NLR), the lymphocyte-to-monocyte ratio (LMR) or the systemic immune-inflammation index (SII). In their study, Pierrakos et al. reviewed the emergence of numerous new inflammatory markers and pointed out that the majority were evaluated by less than five studies and even more were evaluated by studies with small numbers, or that these studies answered a specific clinical question rather than addressing their general diagnostic or prognostic properties [36]. A state of play seems to be necessary for these new ratios as biomarkers of inflammation.

## Limitations

Firstly, this was a retrospective study, which means that although we added a number of exclusion criteria (including comorbidities that alter blood cell count and therefore the number of circulating lymphocytes and platelets), the data were subject to further confounding factors.

With the aim of keeping away the risk of confounding factors, we excluded patients who were potentially more severe and more frequently hospitalized. Similarly, we did not take into account patients who received ambulatory care. In fact, we probably minimized the effects studied, the same way that we cannot, with our results, discriminate between patients with “mild and common”, “moderate” and “severe” forms.

Finally, our patients were exclusively included in the first wave, which had several implications. Firstly, many patients received non-recommended treatments before their admission to the ED, such as antibiotics—which could modify the CBC and which we excluded—or antimalarials. Secondly, patient management has evolved considerably since the first wave, notably with the widespread use of anticoagulants to prevent thromboembolic events and corticoids, which can alter the CBC. Finally, the disease itself has evolved
with the emergence of new variants, the most recent of which appear to be more contagious but less virulent.

**5. Conclusions**

Although the PLR is an interesting marker of inflammation, it does not appear to be a good prognostic marker to discriminate the most severe patients infected with SARS-CoV2 admitted to an ED. A high PLR could, however, be associated with excess mortality. Further studies would be needed to confirm this.

**Author Contributions:** Conceptualization, P.L.B., C.-E.L., L.A.V.; methodology, P.S., L.A.V., F.L.; validation, L.A.V. formal analysis, P.S., L.A.V., F.L.; investigation, P.L.B., L.C., A.R., C.-E.L., L.A.V.; writing—original draft preparation, P.S., L.A.V.; writing—review and editing, All authors; visualization, L.A.V.; supervision, L.A.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** This study was approved by the institution's (Strasbourg University Hospital, France) Ethics Review Board (reference: CE-2020-39).

**Informed Consent Statement:** Patient consent was waived, in accordance with the French legislation who waived the need for informed consent of patients whose data were entirely retrospectively studied.

**Data Availability Statement:** All data analyzed as part of the study are included.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382*, 727–733. [CrossRef] [PubMed]

2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* **2020**, *5*, 536–544. [CrossRef] [PubMed]

3. Tableau de Bord COVID-19. Tableau de Bord COVID-19. Available online: https://dashboard.covid19.data.gouv.fr vue-d-ensemble?location=FRA (accessed on 29 July 2022).

4. Ritchie, H.; Mathieu, E.; Rodés-Guirao, L.; Appel, C.; Giattino, C.; Ortiz-Ospina, E.; Hasell, J.; Macdonald, B.; Dattani, S.; Roser, M.; et al. Our World Data 5 Mars 2020. Available online: https://ourworldindata.org/covid-deaths (accessed on 29 July 2022).

5. Hu, B.; Huang, S.; Yin, L. The cytokine storm and COVID-19. *J. Med. Virol.* **2021**, *93*, 250–256. [CrossRef]

6. Zhang, Y.; Zeng, X.; Jiao, Y.; Li, Z.; Liu, Q.; Ye, J.; Yang, M. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. *Thromb Res.* **2020**, *193*, 110–115. [CrossRef] [PubMed]

7. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.; Hui, D.S.C.; et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N. Engl. J. Med.* **2020**, *382*, 1708–1720. [CrossRef]

8. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* **2020**, *46*, 846–848. [CrossRef]

9. Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W.; et al. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin. Infect. Dis.* **2020**, *71*, 762–768. [CrossRef]

10. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern. Med.* **2020**, *180*, 934. [CrossRef]

11. Henry, B.M.; de Oliveira, M.H.S.; Benoit, S.; Plebani, M.; Lippi, G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. *Clin. Chem. Lab. Med.* **2020**, *58*, 1021–1028. [CrossRef]

12. Wang, F.; Nie, J.; Wang, H.; Zhao, Q.; Xiong, Y.; Deng, L.; Song, S.; Ma, Z.; Mo, P.; Zhang, Y. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. *J. Infect. Dis.* **2020**, *221*, 1762–1769. [CrossRef]

13. Gong, P.; Liu, Y.; Gong, Y.; Chen, G.; Zhang, X.; Wang, S.; Zhou, F.; Duan, R.; Chen, W.; Huang, T.; et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. *J. Neuroinflamm.* **2021**, *18*, 51. [CrossRef]

14. Templeton, A.J.; Ace, O.; McNamara, M.G.; Al-Mubarak, M.; Vera-Badillo, F.E.; Hermanns, T.; Šeruga, B.; Ocaña, A.; Tannock, I.F.; Amir, E. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. *Cancer Epidemiol. Biomark. Prev.* **2014**, *23*, 1204–1212. [CrossRef]
15. Gasparyan, A.Y.; Ayvazyan, L.; Mukanova, U.; Yessirkepov, M.; Kitas, G.D. The Platelet-to-Lymphocyte Ratio as an In-flammatory Marker in Rheumatic Diseases. *Ann. Lab. Med.* **2019**, *39*, 345–357. [CrossRef]

16. Akboga, M.K.; Canpolat, U.; Yayla, C.; Ozcan, F.; Ozeke, O.; Topaloglu, S.; Aras, D. Association of Platelet to Lymphocyte Ratio With Inflammation and Severity of Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease. *Angiology*. **2016**, *67*, 89–95. [CrossRef]

17. Meng, Z.; Yang, J.; Wu, J.; Zheng, X.; Zhao, Y.; He, Y. Association between the platelet-lymphocyte ratio and short-term mortality in patients with non-ST-segment elevation myocardial infarction. *Clin. Cardiol*. **2021**, *44*, 994–1001. [CrossRef]

18. Sun, S.; Cai, X.; Wang, H.; He, G.; Lin, Y.; Lu, B.; Chen, C.; Pan, Y.; Hu, X. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clin. Chim. Acta* **2020**, *507*, 174–180. [CrossRef]

19. Seyit, M.; Avci, E.; Nar, R.; Senol, H.; Yilmaz, A.; Ozen, M.; Oskay, A.; Aybek, H. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. *Am. J. Emerg. Med.* **2021**, *40*, 110–114. [CrossRef]

20. Wei, P.F. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). *Chin. Med. J. (Engl.)* **2020**, *133*, 1087–1095.

21. Wang, H.; Xing, Y.; Yao, X.; Li, Y.; Huang, J.; Tang, J.; Zhu, S.; Zhang, Y.; Xiao, J. Retrospective Study of Clinical Features of COVID-19 in Inpatients and Their Association with Disease Severity. *Med. Sci. Monit.* **2020**, *26*, e927674-1-e927674-9. Available online: https://www.medscimonit.com/abstract/index/idArt/927674 (accessed on 29 July 2022). [CrossRef]

22. Wang, W.; Zhao, Z.; Liu, X.; Liu, G.; Xie, D.; Xu, Z.; Zhao, J.; Zhang, J. Clinical features and potential risk factors for discerning the critical cases and predicting the outcome of patients with COVID-19. *J. Clin. Lab. Anal.* **2020**, *34*, e23547. Available online: https://onlinelibrary.wiley.com/doi/10.1002/jcla.23547 (accessed on 29 July 2022). [CrossRef]

23. Wang, X.; Li, X.; Shang, Y.; Wang, J.; Zhang, X.; Su, D.; Zhao, S.; Wang, Q.; Liu, L.; Li, Y.; et al. Ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte predict all-cause mortality in inpatients with coronavirus disease 2019 (COVID-19): A retrospective cohort study in a single medical centre. *Epidemiol. Infect.* **2020**, *148*, e211. [CrossRef] [PubMed]

24. Wang, R.; He, M.; Yin, W.; Liao, X.; Wang, B.; Jin, X.; Ma, Y.; Yue, J.; Bai, L.; Liu, D.; et al. The Prognostic Nutritional Index is associated with mortality of COVID-19 patients in Wuhan, China. *J. Clin. Lab. Anal.* **2020**, *34*, e23566. Available online: https://onlinelibrary.wiley.com/doi/10.1002/jcla.23566 (accessed on 29 July 2022). [CrossRef] [PubMed]

25. Dessie, Z.G.; Zewotir, T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. *BMC Infect. Dis.* **2021**, *21*, 855. [CrossRef]

26. You, J.; Zhu, G.-Q.; Xie, L.; Liu, W.-Y.; Shi, L.; Wang, O.-C.; Huang, Z.-H.; Braddock, M.; Guo, G.-L.; Zheng, M.-H. Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. *Oncotarget* **2016**, *7*, 25516–25527. [CrossRef]

27. Info Cancer, La Corticothérapie. Available online: http://www.arcagy.org/infocancer/traitement-du-cancer/traitements-systemiques/hormonotherapie/la-corticothérapie.html/ (accessed on 29 July 2022).

28. Covid-19: Conditions D'utilisation de la Dexaméthasone ou D'autres Corticoïdes de Substitution chez les Patients Hospitalisés. 2020. 34p. Available online: https://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20201019_utideladexetdautcordanlecov.pdf (accessed on 29 July 2022).

29. Fathi, N.; Rezaei, N. Lymphopenia in COVID-19: Therapeutic opportunities. *Cell Biol. Int.* **2020**, *44*, 1792–1797. [CrossRef]

30. Tan, L.; Wang, Q.; Zhang, D.; Ding, J.; Huang, Q.; Tang, Y.Q.; Wang, Q.; Miao, H. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. *Signal Transduct. Target. Ther.* **2020**, *5*, 33. [CrossRef]

31. Barale, C.; Melchionda, E.; Morotti, A.; Russo, I. Prothrombotic Phenotype in COVID-19: Focus on Platelets. *Int. J. Mol. Sci.* **2021**, *22*, 13638. [CrossRef]

32. Zhang, J.; Cao, Y.; Tan, G.; Dong, X.; Wang, B.; Lin, J.; Yan, Y.Q.; Liu, G.H.; Akdis, M.; Akdis, C.A.; et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. *Allergy* **2021**, *76*, 533–550. [CrossRef]

33. Liu, J.; Li, S.; Liu, J.; Liang, B.; Wang, X.; Wang, H.; Li, W.; Tong, Q.; Yi, J.; Zhao, L.; et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* **2020**, *55*, 102763. [CrossRef]

34. Li, Q.; Cao, Y.; Chen, L.; Wu, D.; Yu, J.; Wang, H.; He, W.; Dong, F.; Chen, W.; Chen, W.; et al. Hematological features of persons with COVID-19. *Leukemia* **2020**, *34*, 2163–2172. [CrossRef]

35. Yang, X.; Yang, Q.; Wang, Y.; Wu, Y.; Xu, J.; Yu, Y.; Shang, Y. Thrombocytopenia and its association with mortality in patients with COVID-19. *J. Thromb. Haemost.* **2020**, *18*, 1469–1472. [CrossRef]

36. Pierrakos, C.; Velissaris, D.; Bisdorff, M.; Marshall, J.C.; Vincent, J.L. Biomarkers of sepsis: Time for a reappraisal. *Crit. Care* **2020**, *24*, 287. [CrossRef]